JP2024119812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024119812A5 JP2024119812A5 JP2024079079A JP2024079079A JP2024119812A5 JP 2024119812 A5 JP2024119812 A5 JP 2024119812A5 JP 2024079079 A JP2024079079 A JP 2024079079A JP 2024079079 A JP2024079079 A JP 2024079079A JP 2024119812 A5 JP2024119812 A5 JP 2024119812A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- ceutically acceptable
- compound according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000003376 axonal effect Effects 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 claims 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958178P | 2020-01-07 | 2020-01-07 | |
| US62/958,178 | 2020-01-07 | ||
| US202063065736P | 2020-08-14 | 2020-08-14 | |
| US63/065,736 | 2020-08-14 | ||
| PCT/US2021/012333 WO2021142006A1 (en) | 2020-01-07 | 2021-01-06 | Inhibitors of sarm1 |
| JP2022541796A JP7490781B2 (ja) | 2020-01-07 | 2021-01-06 | Ｓａｒｍ１の阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541796A Division JP7490781B2 (ja) | 2020-01-07 | 2021-01-06 | Ｓａｒｍ１の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024119812A JP2024119812A (ja) | 2024-09-03 |
| JP2024119812A5 true JP2024119812A5 (https=) | 2025-01-07 |
| JP7659110B2 JP7659110B2 (ja) | 2025-04-08 |
Family
ID=74505335
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541796A Active JP7490781B2 (ja) | 2020-01-07 | 2021-01-06 | Ｓａｒｍ１の阻害剤 |
| JP2024079079A Active JP7659110B2 (ja) | 2020-01-07 | 2024-05-15 | Ｓａｒｍ１の阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541796A Active JP7490781B2 (ja) | 2020-01-07 | 2021-01-06 | Ｓａｒｍ１の阻害剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12331033B2 (https=) |
| EP (1) | EP4087838A1 (https=) |
| JP (2) | JP7490781B2 (https=) |
| KR (1) | KR20220164471A (https=) |
| CN (1) | CN115175900B (https=) |
| AU (2) | AU2021206651B2 (https=) |
| BR (1) | BR112022013388A2 (https=) |
| CA (1) | CA3163265A1 (https=) |
| CL (1) | CL2022001825A1 (https=) |
| CO (1) | CO2022009514A2 (https=) |
| CR (1) | CR20220375A (https=) |
| DO (1) | DOP2022000141A (https=) |
| EC (1) | ECSP22053394A (https=) |
| IL (1) | IL294507A (https=) |
| JO (1) | JOP20220167A1 (https=) |
| MX (1) | MX2022008395A (https=) |
| MY (1) | MY206478A (https=) |
| PE (1) | PE20230165A1 (https=) |
| TW (1) | TW202140437A (https=) |
| UA (1) | UA128949C2 (https=) |
| WO (1) | WO2021142006A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| US12435084B2 (en) | 2020-04-09 | 2025-10-07 | Eli Lilly And Company | Indazole derivatives as inhibitors of SARM1 |
| US12606558B2 (en) | 2020-04-09 | 2026-04-21 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of SARM1 |
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| TWI904906B (zh) | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| CN116438171A (zh) * | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| EP4376840A4 (en) * | 2021-07-28 | 2025-05-21 | Nura Bio, Inc. | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS |
| JP2023030679A (ja) * | 2021-08-23 | 2023-03-08 | 国立大学法人 岡山大学 | 化合物、神経系疾患の予防又は治療薬 |
| IL321043A (en) * | 2022-12-15 | 2025-07-01 | Sironax Ltd | SARM1 modulators, their preparations and uses |
| EP4655069A1 (en) | 2023-01-24 | 2025-12-03 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
| WO2024158607A1 (en) | 2023-01-24 | 2024-08-02 | Disarm Therapeutics, Inc. | Substituted 1h-pyrazole-4-carboxamides as sarm1 inhibitors |
| CN121712761A (zh) * | 2023-08-25 | 2026-03-20 | 豪夫迈·罗氏有限公司 | 用于治疗神经退行性病症的作为sarm1抑制剂的吡唑衍生物 |
| TW202545928A (zh) | 2024-01-25 | 2025-12-01 | 比利時商優稀美生物醫藥股份有限公司 | 吡咯啶酮衍生物 |
| TW202543611A (zh) * | 2024-03-27 | 2025-11-16 | 美商費斯製藥有限公司 | Ｈｐｄ抑制劑組成物及使用方法 |
| GB202408068D0 (en) | 2024-06-06 | 2024-07-24 | Univ London | Treatment of cancer of the central nervous system |
| CN118593490B (zh) * | 2024-06-28 | 2024-11-19 | 华中农业大学 | Ml216在制备抗猪德尔塔冠状病毒药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| AR043057A1 (es) | 2002-10-30 | 2005-07-13 | Vertex Pharma | Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa |
| CN1732164A (zh) * | 2002-10-30 | 2006-02-08 | 沃泰克斯药物股份有限公司 | 可用作rock及其他蛋白质激酶抑制剂的组合物 |
| AU2003300099A1 (en) | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2005105780A2 (en) * | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| CN101111479A (zh) * | 2004-12-16 | 2008-01-23 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的吡啶酮 |
| US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| EP2036905B1 (en) * | 2006-06-28 | 2012-12-12 | ASKA Pharmaceutical Co., Ltd. | Pyridylisoxazole derivative |
| CA2662359A1 (en) * | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
| JP2011506563A (ja) | 2007-12-20 | 2011-03-03 | ノバルティス アーゲー | ビスチアゾール誘導体、その製造方法および医薬品としてのその使用 |
| EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8785468B2 (en) * | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| RU2570907C2 (ru) * | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| WO2015112847A1 (en) * | 2014-01-24 | 2015-07-30 | Confluence Life Sciences, Inc. | Arylpyridinone itk inhibitors for treating inflammation and cancer |
| JP2018515623A (ja) * | 2015-05-18 | 2018-06-14 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | キナーゼ阻害剤としての複素環式化合物 |
| JP7044789B2 (ja) | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用 |
| WO2018107056A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels |
| CA3108669A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN111253333A (zh) * | 2018-11-30 | 2020-06-09 | 青岛清原化合物有限公司 | N-(1,3,4-噁二唑-2-基)芳基甲酰胺类或其盐、制备方法、除草组合物和应用 |
| EP3897670A4 (en) * | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| US12595252B2 (en) | 2019-06-14 | 2026-04-07 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| US12435084B2 (en) * | 2020-04-09 | 2025-10-07 | Eli Lilly And Company | Indazole derivatives as inhibitors of SARM1 |
| US12404265B2 (en) * | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| CN116438171A (zh) * | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
-
2021
- 2021-01-06 WO PCT/US2021/012333 patent/WO2021142006A1/en not_active Ceased
- 2021-01-06 KR KR1020227027204A patent/KR20220164471A/ko not_active Ceased
- 2021-01-06 JP JP2022541796A patent/JP7490781B2/ja active Active
- 2021-01-06 IL IL294507A patent/IL294507A/en unknown
- 2021-01-06 MY MYPI2022003584A patent/MY206478A/en unknown
- 2021-01-06 UA UAA202202347A patent/UA128949C2/uk unknown
- 2021-01-06 PE PE2022001414A patent/PE20230165A1/es unknown
- 2021-01-06 BR BR112022013388A patent/BR112022013388A2/pt unknown
- 2021-01-06 CN CN202180019643.9A patent/CN115175900B/zh active Active
- 2021-01-06 TW TW110100350A patent/TW202140437A/zh unknown
- 2021-01-06 CR CR20220375A patent/CR20220375A/es unknown
- 2021-01-06 AU AU2021206651A patent/AU2021206651B2/en active Active
- 2021-01-06 EP EP21703092.3A patent/EP4087838A1/en active Pending
- 2021-01-06 MX MX2022008395A patent/MX2022008395A/es unknown
- 2021-01-06 CA CA3163265A patent/CA3163265A1/en active Pending
- 2021-08-17 US US17/404,523 patent/US12331033B2/en active Active
-
2022
- 2022-07-05 DO DO2022000141A patent/DOP2022000141A/es unknown
- 2022-07-05 CL CL2022001825A patent/CL2022001825A1/es unknown
- 2022-07-06 CO CONC2022/0009514A patent/CO2022009514A2/es unknown
- 2022-07-07 EC ECSENADI202253394A patent/ECSP22053394A/es unknown
- 2022-07-07 JO JOP/2022/0167A patent/JOP20220167A1/ar unknown
-
2024
- 2024-02-06 AU AU2024200703A patent/AU2024200703A1/en not_active Withdrawn
- 2024-05-15 JP JP2024079079A patent/JP7659110B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024119812A5 (https=) | ||
| AU780678B2 (en) | New use of compounds as antibacterial agents | |
| JP2024508755A5 (https=) | ||
| JP2022545359A5 (https=) | ||
| JP2022520061A5 (https=) | ||
| JP2022519744A5 (https=) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| JP2020533352A5 (https=) | ||
| JP2019517587A5 (https=) | ||
| JP2023533485A5 (https=) | ||
| JP2020512337A5 (https=) | ||
| JP2023524039A5 (https=) | ||
| JP2023546536A5 (https=) | ||
| JP2017506257A5 (https=) | ||
| JP2024528127A5 (https=) | ||
| JP2018507257A5 (https=) | ||
| JP2022541938A5 (https=) | ||
| JP2022541545A5 (https=) | ||
| JP2005517677A5 (https=) | ||
| HUP0203121A2 (hu) | Szubsztituált benzimidazolokat tartalmazó gyógyszerkészítmény és alkalmazása | |
| JP5113323B2 (ja) | ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物 | |
| JP2019524888A5 (https=) | ||
| JP2020534266A5 (https=) | ||
| JP2024518558A5 (https=) |